eribulin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics; mitotic inhibitors, tubulin binders 4171 253128-41-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eribulin mesylate
  • eribulin
  • halaven
  • E7389
  • eribulin mesilate
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype.
  • Molecular weight: 729.91
  • Formula: C40H59NO11
  • CLOGP: 0.14
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 2
  • TPSA: 146.39
  • ALOGS: -3.96
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 1.46 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.75 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.43 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 37.80 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 10.40 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC 13
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
March 17, 2011 EMA
Nov. 15, 2010 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myelosuppression 1796.02 32.93 550 12973 53041 90561883
Malignant neoplasm progression 1503.26 32.93 572 12951 106298 90508626
Neutropenia 1482.93 32.93 702 12821 224202 90390722
Febrile neutropenia 859.14 32.93 434 13089 157915 90457009
Neutrophil count decreased 674.55 32.93 288 13235 71244 90543680
Metastases to bone 442.90 32.93 160 13363 25345 90589579
White blood cell count decreased 439.24 32.93 286 13237 166823 90448101
Neuropathy peripheral 436.69 32.93 265 13258 136705 90478219
Metastases to liver 431.18 32.93 162 13361 28645 90586279
Interstitial lung disease 359.95 32.93 191 13332 76214 90538710
Leukopenia 333.99 32.93 200 13323 100510 90514414
Pseudocirrhosis 279.44 32.93 56 13467 888 90614036
Disease progression 273.55 32.93 209 13314 156406 90458518
Metastases to lung 214.21 32.93 83 13440 15908 90599016
Neoplasm progression 203.07 32.93 109 13414 44377 90570547
Breast cancer metastatic 200.77 32.93 78 13445 15054 90599870
Metastases to central nervous system 176.10 32.93 74 13449 17468 90597456
Palmar-plantar erythrodysaesthesia syndrome 157.55 32.93 79 13444 27944 90586980
Mucosal inflammation 156.73 32.93 101 13422 57524 90557400
Metastases to lymph nodes 126.38 32.93 52 13471 11637 90603287
Osteonecrosis of jaw 125.10 32.93 76 13447 39027 90575897
Thrombocytopenia 109.65 32.93 145 13378 208580 90406344
Pyrexia 96.71 32.93 265 13258 660220 89954704
Haematotoxicity 93.74 32.93 43 13480 12492 90602432
Anaemia 92.08 32.93 178 13345 352624 90262300
Hepatic function abnormal 85.52 32.93 64 13459 46224 90568700
Metastases to skin 80.01 32.93 24 13499 2116 90612808
Hormone receptor positive breast cancer 77.92 32.93 19 13504 762 90614162
Pleural effusion 73.43 32.93 87 13436 111904 90503020
Breast cancer 68.85 32.93 60 13463 53701 90561223
Stomatitis 63.67 32.93 132 13391 274566 90340358
Hyperchlorhydria 60.79 32.93 19 13504 1922 90613002
PIK3CA-activated mutation 56.02 32.93 16 13507 1188 90613736
Pneumonitis 55.96 32.93 49 13474 44121 90570803
Abdominal discomfort 55.87 32.93 4 13519 477324 90137600
Hypersensitivity 55.64 32.93 3 13520 454674 90160250
Pneumothorax 55.56 32.93 35 13488 19132 90595792
Breast cancer recurrent 54.49 32.93 23 13500 5480 90609444
Polyneuropathy 52.78 32.93 34 13489 19307 90595617
Folate deficiency 51.68 32.93 19 13504 3146 90611778
Lymphopenia 49.91 32.93 35 13488 22846 90592078
Drug hypersensitivity 48.66 32.93 6 13517 463603 90151321
Hepatic failure 48.18 32.93 43 13480 39685 90575239
Ascites 46.98 32.93 46 13477 47694 90567230
Tumour marker increased 46.83 32.93 21 13502 5786 90609138
Metastases to the mediastinum 45.79 32.93 12 13511 645 90614279
Platelet count decreased 45.69 32.93 77 13446 136892 90478032
Decreased appetite 45.19 32.93 141 13382 376399 90238525
Arthralgia 44.48 32.93 31 13492 778491 89836433
Odynophagia 43.59 32.93 23 13500 9020 90605904
Herpes simplex encephalitis 40.72 32.93 10 13513 413 90614511
Sepsis 39.97 32.93 85 13438 179729 90435195
Metastases to spinal cord 39.05 32.93 9 13514 282 90614642
Weight increased 38.04 32.93 8 13515 417919 90197005
Pruritus 37.45 32.93 17 13506 541508 90073416
Peripheral swelling 37.41 32.93 8 13515 413098 90201826
Pain 37.34 32.93 57 13466 996284 89618640
Metastases to bone marrow 36.94 32.93 10 13513 609 90614315
Metastases to pleura 36.09 32.93 13 13510 2031 90612893
Infusion related reaction 35.90 32.93 9 13514 416771 90198153
Protein total increased 35.86 32.93 15 13508 3494 90611430
Hyperglycaemia 35.72 32.93 41 13482 50929 90563995
Peripheral sensory neuropathy 34.86 32.93 20 13503 9230 90605694
Lymphangiosis carcinomatosa 34.73 32.93 12 13511 1660 90613264
Metastatic neoplasm 34.38 32.93 16 13507 4799 90610125
Swelling 34.30 32.93 10 13513 419048 90195876
Depression 33.80 32.93 3 13520 300598 90314326
Skin mass 33.29 32.93 18 13505 7412 90607512

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 99.53 41.39 48 510 185655 42435122
Neutropenia 93.28 41.39 47 511 199384 42421393
Myelosuppression 72.43 41.39 25 533 40436 42580341

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myelosuppression 1757.09 30.19 570 11174 93770 110483785
Neutropenia 1165.16 30.19 630 11114 373990 110203565
Malignant neoplasm progression 919.23 30.19 421 11323 174146 110403409
Neutrophil count decreased 645.84 30.19 295 11449 120646 110456909
Febrile neutropenia 587.49 30.19 383 11361 316384 110261171
White blood cell count decreased 455.71 30.19 290 11454 229100 110348455
Neuropathy peripheral 324.45 30.19 214 11530 179063 110398492
Metastases to bone 282.00 30.19 111 11633 31261 110546294
Pseudocirrhosis 280.74 30.19 53 11691 870 110576685
Leukopenia 265.13 30.19 176 11568 148615 110428940
Interstitial lung disease 243.83 30.19 163 11581 139171 110438384
Metastases to liver 222.46 30.19 97 11647 35289 110542266
Disease progression 174.68 30.19 169 11575 243865 110333690
Metastases to lung 167.34 30.19 70 11674 22993 110554562
Breast cancer metastatic 142.06 30.19 51 11693 11130 110566425
Metastases to central nervous system 131.92 30.19 59 11685 22758 110554797
Osteonecrosis of jaw 108.26 30.19 66 11678 47951 110529604
Metastases to lymph nodes 103.60 30.19 44 11700 14988 110562567
Neoplasm progression 99.63 30.19 70 11674 64525 110513030
Pyrexia 87.29 30.19 250 11494 898015 109679540
Mucosal inflammation 86.96 30.19 76 11668 96065 110481490
Thrombocytopenia 84.96 30.19 141 11603 348744 110228811
Metastases to skin 81.81 30.19 23 11721 2276 110575279
Stomatitis 72.26 30.19 114 11630 270128 110307427
Palmar-plantar erythrodysaesthesia syndrome 64.50 30.19 45 11699 40980 110536575
Anaemia 62.69 30.19 162 11582 546924 110030631
Hepatic function abnormal 62.14 30.19 61 11683 89234 110488321
Pneumothorax 60.90 30.19 41 11703 35244 110542311
Hyperchlorhydria 60.70 30.19 18 11726 2151 110575404
Hormone receptor positive breast cancer 56.71 30.19 13 11731 564 110576991
Haematotoxicity 55.39 30.19 32 11712 21050 110556505
Breast cancer recurrent 54.38 30.19 19 11725 3827 110573728
Pneumonitis 49.04 30.19 50 11694 76481 110501074
Decreased appetite 48.50 30.19 135 11609 475711 110101844
Folate deficiency 48.05 30.19 18 11726 4420 110573135
Breast cancer 44.25 30.19 35 11709 38507 110539048
Pleural effusion 43.40 30.19 72 11672 177637 110399918
Metastases to the mediastinum 42.69 30.19 11 11733 782 110576773
Polyneuropathy 38.76 30.19 30 11714 31982 110545573
Herpes simplex encephalitis 37.23 30.19 10 11734 835 110576720
Platelet count decreased 37.01 30.19 78 11666 230365 110347190
Protein total increased 36.48 30.19 15 11729 4709 110572846
Odynophagia 35.97 30.19 21 11723 14080 110563475
Drug hypersensitivity 34.35 30.19 4 11740 454086 110123469
Hepatic failure 32.03 30.19 38 11706 68701 110508854
Hypersensitivity 31.99 30.19 3 11741 403995 110173560
Skin mass 31.51 30.19 17 11727 9799 110567756
Metastases to bone marrow 30.94 30.19 9 11735 1005 110576550
Recurrent cancer 30.33 30.19 12 11732 3411 110574144
Pruritus 30.21 30.19 12 11732 581548 109996007

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX41 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA PE N0000175085 Microtubule Inhibition
FDA EPC N0000175592 Microtubule Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:61951 microtubule-destabilising agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitox show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liposarcoma indication 254829001 DOID:3382
Metastatic Breast Carcinoma indication
Constipation contraindication 14760008 DOID:2089
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG/2ML (0.5MG/ML) HALAVEN EISAI INC N201532 Nov. 15, 2010 RX SOLUTION INTRAVENOUS Sept. 13, 2025 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
1MG/2ML (0.5MG/ML) HALAVEN EISAI INC N201532 Nov. 15, 2010 RX SOLUTION INTRAVENOUS March 13, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR IC50 8.23 IUPHAR SCIENTIFIC LITERATURE

External reference:

IDSource
4030296 VUID
N0000182254 NUI
D08914 KEGG_DRUG
441045-17-6 SECONDARY_CAS_RN
4030296 VANDF
4030302 VANDF
C2350866 UMLSCUI
CHEMBL1683590 ChEMBL_ID
CHEMBL1683544 ChEMBL_ID
DB08871 DRUGBANK_ID
C490954 MESH_SUPPLEMENTAL_RECORD_UI
6813 IUPHAR_LIGAND_ID
8854 INN_ID
LR24G6354G UNII
11354606 PUBCHEM_CID
1045452 RXNORM
178296 MMSL
27619 MMSL
385128 MMSL
d07716 MMSL
013558 NDDF
013559 NDDF
448800004 SNOMEDCT_US
708166000 SNOMEDCT_US
767582004 SNOMEDCT_US
CHEBI:70710 CHEBI
6K9 PDB_CHEM_ID
LR24G6354G INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ERIBULIN MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9167 INJECTION 0.50 mg INTRAVENOUS ANDA 32 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3391 INJECTION 0.50 mg INTRAVENOUS ANDA 28 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10019-080 INJECTION 0.50 mg INTRAVENOUS ANDA 29 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10019-080 INJECTION 0.50 mg INTRAVENOUS ANDA 29 sections
ERIBULIN MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 39822-2080 INJECTION 0.50 mg INTRAVENOUS ANDA 32 sections
ERIBULIN MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 40033-364 INJECTION 0.50 mg INTRAVENOUS ANDA 33 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 43598-125 INJECTION 0.50 mg INTRAVENOUS ANDA 27 sections
Halaven HUMAN PRESCRIPTION DRUG LABEL 1 43624-002 INJECTION 1 mg INTRAVENOUS NDA 2 sections
eribulin mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6289 INJECTION 0.50 mg INTRAVENOUS ANDA 28 sections
eribulin mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6435 INJECTION 0.50 mg INTRAVENOUS ANDA 28 sections
Halaven HUMAN PRESCRIPTION DRUG LABEL 1 62856-389 INJECTION 0.50 mg INTRAVENOUS NDA 33 sections
Halaven HUMAN PRESCRIPTION DRUG LABEL 1 62856-389 INJECTION 0.50 mg INTRAVENOUS NDA 33 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 68001-656 SOLUTION 0.50 mg INTRAVENOUS ANDA 30 sections
eribulin mesylate Human Prescription Drug Label 1 68083-592 INJECTION 0.50 mg INTRAVENOUS ANDA 27 sections
ERIBULIN MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 68462-770 INJECTION 0.50 mg INTRAVENOUS ANDA 33 sections
ERIBULIN MESYLATE Human Prescription Drug Label 1 70095-080 INJECTION 0.50 mg INTRAVENOUS ANDA 28 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 71731-4171 INJECTION 0.50 mg INTRAVENOUS ANDA 32 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 72603-368 SOLUTION 0.50 mg INTRAVENOUS ANDA 32 sections
Eribulin Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 81298-3890 SOLUTION 0.50 mg INTRAVENOUS ANDA 30 sections